{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"1.6","value":"1.4"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"1.4","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"FAS: Enrolled participants who have received at least one dose of treatment. Participants who were enrolled but did not subsequently receive study intervention are not included in the analysis. The analysis for TTR assessed by investigator was based on the responders in the FAS of each cohort.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Time To Response (TTR) , Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Month"}